Mohamad Khawandanah, MD
Internal Medicine · Oklahoma City, OKNPI 1982867693
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $221 of the $274 with a category attached, or 80.6%. 7 manufacturers reported payments, led by Novartis at 38.3% of the total. Reporting peaked in 2020 at $105 and has fallen 80.6% since, to $20 in 2025. That places this record below the midpoint for internal medicine clinicians in OK, where the typical reported total is $246.
Across 9 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$105
- Apellis Pharmaceuticals, Inc.$53
- Sanofi$35
- AstraZeneca$28
- AbbVie$20
- Incyte Corporation$18
- plus $15 from 1 others
Across 3 payments — averaging $2801.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Syndax Pharmaceuticals, Inc.$5K
- Ablynx NV$4K
What the payments were for
- Food & beverage$22181%
- Education$5319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $105 |
| Apellis Pharmaceuticals, Inc. | 2 | $53 |
| Sanofi | 1 | $35 |
| AstraZeneca | 2 | $28 |
| AbbVie | 1 | $20 |
| Incyte Corporation | 1 | $18 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KYMRIAH$105
How this compares
$274 in reported general payments places this provider in the 50th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SprycelDasatinib | 54 | $739,843 |
| JakafiRuxolitinib Phosphate | 38 | $525,162 |
| EmpaveliPegcetacoplan | 11 | $442,055 |
| BosulifBosutinib | 18 | $344,751 |
| PromactaEltrombopag Olamine | 12 | $313,548 |
| RezurockBelumosudil Mesylate | 11 | $260,913 |
| TasignaNilotinib Hcl | 13 | $130,930 |
| ProcritEpoetin Alfa | 15 | $79,216 |
| VenclextaVenetoclax | 16 | $45,314 |
| Posaconazole | 23 | $25,255 |
| Imatinib Mesylate | 33 | $10,572 |
| Atovaquone | 24 | $10,003 |
| Fluconazole | 23 | $1,417 |
| ValacyclovirValacyclovir Hcl | 17 | $1,075 |
| Hydroxyurea | 19 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $18 | $525,16238 claims |
| NovartisPromacta, Tasigna | $105 | $444,47925 claims |
| Apellis Pharmaceuticals, Inc.Empaveli | $53 | $442,05511 claims |
| AbbVieVenclexta | $20 | $45,31416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.